Pegcetacoplan Lowers Proteinuria in Complement-Mediated Glomerular Diseases: NEJM
In a phase three, double blind, placebo controlled trial, pegcetacoplan significantly reduced proteinuria compared with placebo in patients with recurrent C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, highlighting its therapeutic potential in rare complement mediated kidney diseases.
C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis generally result in glomerular C3 deposition and progressive, irreversible kidney damage. The efficacy and safety of pegcetacoplan, a complement C3 and C3b inhibitor, have remained uncertain in these conditions. Investigators conducted a phase three, double blind, placebo controlled trial involving adolescents and adults with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis, including patients with native kidney disease as well as those with disease recurrence after kidney transplantation. Participants were randomly assigned to receive pegcetacoplan or placebo. The primary outcome assessed changes in urinary protein excretion over time.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.